Pharma Newsletter- July 31 to August 04, 2017

India Infoline News Service | Mumbai | August 05, 2017 10:46 IST

This week, “On the directions of the Ministry of Commerce, Pharmexcil and the CSIR-Indian Institute of Chemical Technology (IICT) are working for reducing the dependency of Indian pharmaceutical industry on Chinese raw material imports, as per the leading news agency”.

Top News:
 
Divi’s Lab's inspection ends with no critical observations
 
Pharma major, Divi’s Laboratories, in a BSE filing on Friday informed that the inspection of its unit-II Vishakhapatnam has concluded successfully with no critical observation. Read more
 
Biocon’s Bengaluru plant gets USFDA form 483 with 10 observations
 
Biotechnology industry player, Biocon slipped 6.90% to Rs 349.40 per share at 09:39 hours on BSE after USFDA issued a form 483 with 10 observations for the Bengaluru plant. Read more
 
Lupin gets USFDA nod to market Rosuvastatin Calcium
 
Pharma major, Lupin announced on Thursday that the company has received the United States Food and Drug Administration (USFDA) final approval to market Rosuvastatin Calcium Tablet 5 mg, 10 mg, 20 mg and 40 mg. Read more
 
Centre eyeing to reduce drug input imports from China
 
On the directions of the Ministry of Commerce, Pharmexcil and the CSIR-Indian Institute of Chemical Technology (IICT) are working for reducing the dependency of Indian pharmaceutical industry on Chinese raw material imports, as per the leading news agency. Read more

Disclaimer: The contents herein is specifically prepared by ‘Dalal Street Investment Journal’, and is for your information & personal consumption only. India Infoline Limited or Dalal Street Investment Journal do not guarantee the accuracy, correctness, completeness or reliability of information contained herein and shall not be held responsible.

 

Advertisements

  • Save upto Rs.2.67 lakh with Pradhan Mantri Awas Yojana ...Know more
  • Now Save Rs.3150 on your Demat Account ...Click here
  • Now get IIFL Personal Loan in just 8* hours...APPLY NOW!
  • Get the most detailed result analysis on the web - Real Fast!
  • Actionable & Award-Winning Research on 500 Listed Indian Companies.